Quick Takeaways
- Orca Capital AG filed SCHEDULE 13G/A for Silexion Therapeutics Corp Ordinary Shares, par value $0.0135 per share (SLXN).
- Disclosed ownership: 4.9%.
- Date of event: 11 Sep 2025.
Orca Capital AG - 11 Sep 2025 SCHEDULE 13G/A Report for Silexion Therapeutics Corp Ordinary Shares, par value $0.0135 per share (SLXN)
- Filing Manager
- Orca Capital AG
- Reporting Manager
- Orca Capital AG
- Symbol
- SLXN
- Shares outstanding
- 2,233,306 shares
- Disclosed Ownership
- 109,432 shares
- Ownership
- 4.9%
- Form type
- SCHEDULE 13G/A
- Filing time
- 15 Sep 2025, 17:23:28 UTC
- Date of event
- 11 Sep 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Orca Capital AG disclosed 4.9% ownership in Silexion Therapeutics Corp Ordinary Shares, par value $0.0135 per share (SLXN) on 11 Sep 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 15 Sep 2025, 17:23.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Orca Capital AG | 4.9% | 109,432 | 109,432 | 0 | /s/ Thomas Konig | Thomas Konig/Director |